Photo by Turgay Koca on Pexels
N07.5: Nefropati Herediter - Glomerulonefritis Mesangiokapiler Difus
📚 Daftar Pustaka (APA 7)
[1]
Alpers CE, Bijol V, Chang A. Glomerulonephritis. In: Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2021.
[2]
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: A new look at an old entity. N Engl J Med. 2019;381(5):464-475.
[3]
Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy: Understanding a disease continuum of complement-mediated glomerulonephritis. Nat Rev Nephrol. 2019;15(3):129-143.
[4]
Fakhouri F, Frémeaux-Bacchi V. How does complement affect kidney disease? Kidney Int. 2020;98(4):801-804.
[5]
Riedl M, Thorner P, Licht C. C3 Glomerulopathy in children. Pediatr Nephrol. 2020;35(4):555-568.
[6]
Bomback AS, Kleyer AS, Gharavi AG. Complement and glomerular disease. In: Gilbert SJ, Weiner DE, eds. National Kidney Foundation's Primer on Kidney Diseases. 7th ed. Elsevier; 2021.
[7]
Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathy. Nat Rev Nephrol. 2019;11(1):14-26.
[8]
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: Classification and clinical and pathological features. Clin J Am Soc Nephrol. 2020;15(1):110-118.
[9]
Nester CM, Smith RJ. Complement inhibition in C3 glomerulopathy. Clin J Am Soc Nephrol. 2020;15(9):1342-1350.
[10]
World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems. 10th Revision. WHO; 2019.